In May, it announced it would acquire SiteOne Therapeutics, a drugmaker with a promising investigational medicine for pain. In January, it grew its oncology pipeline through the acquisition of a …
Does This $856 Million Investment Make Eli Lilly Stock a Buy?
view original post